|
Press Releases |
|
|
|
Thursday, March 30, 2023 |
|
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq |
Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced the completion of its business combination (the "Business Combination") with Maxpro Capital Acquisition Corp. ("Maxpro", Nasdaq: JMAC). more info >> |
|
Tuesday, July 26, 2022 |
|
Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer |
Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced the appointment of Jane Wang, PhD as Chief Scientific Officer. In this role, Dr. Wang will lead the drug discovery pipeline for the Company. She will also serve as Apollomics' China General Manager and will report to the Chief Executive Officer. more info >> |
|
Wednesday, January 12, 2022 |
|
Apollomics Inc. to Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022 |
Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the management team will host two upcoming webcasts to accommodate participants from the U.S. and China. more info >> |
|
Tuesday, January 4, 2022 |
|
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group |
Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer of Apollomics, was recently appointed to Chairman of the Board for the BayHelix Group, effective January 2022. more info >> |
|
Monday, November 22, 2021 |
|
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia |
Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the first patient has been successfully dosed in a Phase 3 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) in China. more info >> |
|
Friday, October 1, 2021 |
|
Edison Oncology and Apollomics Announce Treatment of First Patient by EO1001 (APL-122) in a Phase I/IIa Clinical Trial |
Edison Oncology Holding Corp. ('Edison Oncology'), a company established to develop new therapies targeting the fight against cancer, and Apollomics Inc. ('Apollomics'), an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, reported that the first patient was dosed with EO1001 (APL-122) in a Phase I/IIa clinical trial in patients with advanced solid tumors. more info >> |
|
Tuesday, August 10, 2021 |
|
Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102 |
Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, today announced the successful dosing of the first patient in a Phase I clinical study of APL-102 in patients with advanced solid tumors. more info >> |
|
Thursday, May 20, 2021 |
|
APOLLOMICS INC. ANNOUNCES OFFICIAL OPENING OF SHANGHAI BRANCH |
Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that Apollomics Shanghai Branch has been officially opened and started its operations at Zhangjiang Hi-Tech Park, Pudong District, Shanghai. more info >> |
|
Tuesday, March 9, 2021 |
|
Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer |
Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced the appointment of K. Peony Yu, M.D. as Chief Medical Officer. Dr. Yu will assume the role on March 16, 2021. more info >> |
|
Thursday, March 4, 2021 |
|
Apollomics, Inc Announces Enrollment of First Patient in Phase 1 Clinical Trial of APL-106 (uproleselan injection) in China |
Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the first patient has been successfully enrolled into a Phase 1 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) in China. In February of this year, the two Phase 1 study sites were initiated. more info >> |
|
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Pertamina International Shipping (PIS) Welcomes 2 VLGC Tankers to Its Fleet, Takes Top-Tier Position in ASEAN LPG Transport
May 10, 2024 16:00 HKT/SGT
|
|
|
Q2 Metals Announces Assay Results from Its 2024 Winter Drill Program at the Mia Lithium Property, James Bay Territory, Quebec, Canada
May 10, 2024 15:09 HKT/SGT
|
|
|
Speculation Swirls: ESR (01821.HK) Progresses in Privatization Talks Led by Warburg Pincus
May 10, 2024 11:26 HKT/SGT
|
|
|
Release of "Fugaku-LLM" - a large language model trained on the supercomputer "Fugaku"
May 10, 2024 12:20 JST
|
|
|
InfoComm Asia 2024 "Asia's International Pro AV Exhibition" Returns to Thailand
May 10, 2024 10:30 HKT/SGT
|
|
|
BLUETTI Unlocks Special Mother's Day Offerings, Perfect Gift Ideas for Moms
May 10, 2024 10:00 HKT/SGT
|
|
|
AGILON HEALTH (NYSE: AGL) INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies Agilon Health Investors of a Class Action Lawsuit and May 20, 2024 Lead Plaintiff Deadline
May 10, 2024 08:33 HKT/SGT
|
|
|
SSR MINING (SSRM) INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies SSR Mining Investors of a Class Action Lawsuit and May 17, 2024 Lead Plaintiff Deadline
May 10, 2024 08:26 HKT/SGT
|
|
|
CHEMOURS (NYSE: CC) ALERT: Kaplan Fox & Kilsheimer LLP Reminds Investors of Class Action Lawsuit and May 20, 2024 Lead Plaintiff Deadline
May 10, 2024 08:20 HKT/SGT
|
|
|
DOXIMITY (NYSE: DOCS) ALERT: Kaplan Fox & Kilsheimer LLP Reminds Investors of Class Action Lawsuit and June 17, 2024 Lead Plaintiff Deadline
May 10, 2024 08:13 HKT/SGT
|
|
|
Xtep Announces Strategic Divestiture of K-Swiss and Palladium and Enhanced Financial Structure
May 9, 2024 20:18 HKT/SGT
|
|
|
Paltalk, Inc. Reports Slight Increase in Revenue and 33% Reduction in Net Loss for First Quarter 2024
May 9, 2024 20:39 JST
|
|
|
Honda Opens New R&D Facility in Bengaluru to Accelerate Electrification in India
May 9, 2024 14:13 JST
|
|
|
Malaysian Retail Sector Sees a 173% Growth in Hiring: foundit Insights Tracker
May 9, 2024 12:00 HKT/SGT
|
|
|
Fujitsu introduces "explainable AI" for use in genomic medicine and cancer treatment planning
May 9, 2024 10:41 JST
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|